Show simple item record

dc.contributor.authorSingh, D
dc.contributor.authorAgusti, A
dc.contributor.authorMartinez, FJ
dc.contributor.authorPapi, A
dc.contributor.authorPavord, ID
dc.contributor.authorWedzicha, JA
dc.contributor.authorVogelmeier, CF
dc.contributor.authorHalpin, DMG
dc.date.accessioned2023-06-21T10:34:30Z
dc.date.issued2022-07-01
dc.date.updated2023-06-20T09:11:02Z
dc.description.abstractThe Global Initiative for Chronic Obstructive Lung Disease (GOLD) published its first report for the diagnosis and management of chronic obstructive pulmonary disease (COPD) in 2001 (1). Since then, GOLD has updated it yearly (2), the last time in 2022 (www.goldcopd.org). To do so, GOLD critically evaluates the new evidence since the previous publication and decides whether it merits (or not) inclusion in the most recent update. GOLD publishes specific recommendations and, sometimes, the main arguments behind them, but it often lacks space for a detailed discussion regarding the pros and cons behind each recommendation. To address this limitation, the Scientific Committee of GOLD decided to publish, separately from the main annual update, a series of papers that review and discuss topics of particular current interest for clinical practice. The GOLD 2019 report recommended using blood eosinophil counts (BEC) as part of a precision medicine strategy to identify the most suitable patients for inhaled corticosteroids (ICS) treatment (3). Recent publications have provided further evidence and insights concerning BEC in COPD. Here, we discuss the role of BEC as a COPD biomarker, focusing on new advances and summarizing the associated changes in the GOLD 2022 report (shown in Table 1).en_GB
dc.format.extent17-24
dc.identifier.citationVol. 206, No. 1, pp. 17-24en_GB
dc.identifier.doihttps://doi.org/10.1164/rccm.202201-0209PP
dc.identifier.urihttp://hdl.handle.net/10871/133452
dc.identifierORCID: 0000-0003-2009-4406 (Halpin, David MG)
dc.language.isoenen_GB
dc.publisherAmerican Thoracic Societyen_GB
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pubmed/35737975en_GB
dc.rights© 2022 by the American Thoracic Society. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0. For commercial usage and reprints, please e-mail Diane Gern (dgern@thoracic.org).en_GB
dc.titleBlood eosinophils and chronic obstructive pulmonary disease: A Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 reviewen_GB
dc.typeArticleen_GB
dc.date.available2023-06-21T10:34:30Z
dc.identifier.issn1073-449X
exeter.place-of-publicationUnited States
dc.descriptionThis is the final version. Available from the American Thoracic Society via the DOI in this record. en_GB
dc.identifier.eissn1535-4970
dc.identifier.journalAmerican Journal of Respiratory and Critical Care Medicineen_GB
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en_GB
dcterms.dateAccepted2022-06-23
rioxxterms.versionVoRen_GB
rioxxterms.licenseref.startdate2022-07-01
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2023-06-21T10:29:32Z
refterms.versionFCDVoR
refterms.dateFOA2023-06-21T10:34:34Z
refterms.panelAen_GB
refterms.dateFirstOnline2022-07-01


Files in this item

This item appears in the following Collection(s)

Show simple item record

© 2022 by the American Thoracic Society. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0. For commercial usage and reprints, please e-mail Diane Gern (dgern@thoracic.org).
Except where otherwise noted, this item's licence is described as © 2022 by the American Thoracic Society. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0. For commercial usage and reprints, please e-mail Diane Gern (dgern@thoracic.org).